Understanding how GSTP1 affects advanced prostate cancer
Delineate the Role of GSTP1 in Advanced Prostate Cancer
This study is looking at a protein called GSTP1 to see how it affects advanced prostate cancer that doesn't respond to hormone therapy, and it aims to find out if targeting this protein could help improve treatment options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11090536 on NIH RePORTER |
What this research studies
This research investigates the role of the GSTP1 protein in advanced prostate cancer, particularly in cases that have become resistant to hormone therapy. The study aims to explore how GSTP1 contributes to the aggressive nature of the disease and to evaluate the potential of targeting this protein as a new treatment strategy. Using patient-derived xenograft models, researchers will test the effects of inhibiting GSTP1 alone and in combination with cisplatin, a chemotherapy drug, to determine its therapeutic benefits. The ultimate goal is to uncover mechanisms that drive treatment resistance and to develop more effective therapies for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those whose disease has become resistant to hormone therapy.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone hormone therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for men with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.